Pregnancy Outcomes in HIV-Infected Women Receiving Long-Term Isoniazid Prophylaxis for Tuberculosis and Antiretroviral Therapy

Table 1

Selected characteristics of subjects experiencing pregnancy during the Isoniazid Preventive Therapy Trial, Botswana, 2005–2008 (𝑛=196).

	No.	% or range
Characteristic (𝑛=196)
Age (median, range)	28	19–39
CD4+ lymphocyte count nearest LNMP (median, range) in cells/mm^3	368	41–1231
CD4+ lymphocyte count near LNMP <200 cells/mm^3	31	16%
Maternal BMI (median, range)	22.9	15.6–36.2
Maternal BMI <18.5 near LNMP	17	19%
Pregnancy outcome date range		Nov 26 2005 to Feb 19 2009
Antiretroviral regimen in Pregnancy
Antiretroviral therapy (≥3 drugs from ≥2 classes)	73	37%
AZT or AZT/3TC only	123	63%
Antiretroviral therapy exposure (𝑛=196)
Number of women on ART prior to pregnancy	47
Time on ART before pregnancy (median, range) in days*	347	21–2221
Timing of ART exposure during pregnancy
First, second, and third trimesters	45
First and second trimesters only	7
Second and third trimesters only	8
Third trimester only	8
Timing unknown	5
Isoniazid exposure (𝑛=103)
Time on isoniazid before pregnancy (median, range) in days	341	1–1095
Exposed to isoniazid in pregnancy
First trimester only	11	11%
First and second, trimesters only	21	20%
First, second, and third trimesters	70	68%
Second trimester only	1	1%
Any trimester (total)	103	100%
Pregnancy outcome (𝑛=196)
Live birth	124	63%
Stillbirth	11	6%
Spontaneous (“inevitable”) abortion	6	3%
Neonatal death	4	2%
Premature	42	21%
Term low birth weight	8	4%
Congenital abnormality	1	1%
Maternal death	0	0%

3TC: lamivudine; ART: antiretroviral therapy; AZT: zidovudine; BMI: body mass index; IPT: isoniazid preventive therapy; LNMP: last normal menstrual period.
*Among women with ART start date prior to LNMP (𝑛=47).